“Microdosing GLP-1s avoids side effects.”
What the evidence shows
Standard prescribing already starts at a low dose and steps up slowly — specifically to reduce nausea and other gut side effects. Lower doses generally do mean milder side effects, but also less of the intended effect. "Microdosing" as a distinct, branded protocol is not a defined or studied regimen.
What we still don’t know
There are no controlled trials of sub-therapeutic "microdosing" for either benefit or safety, and no long-term data on it.
Why the claim misleads
It repackages ordinary low-dose titration as a novel hack. "Avoids side effects" overpromises: a lower dose reduces but does not eliminate risk. It can also backfire — a dose chosen mainly to minimize side effects can be too low to actually control blood sugar or deliver the cardiometabolic benefit someone needs, which is its own hazard. And unstandardized dosing — often from non-pharmacy sources — adds dangers that have nothing to do with the dose size.
Graded by The Peptide Era · evidence, not hype